0000000001138685

AUTHOR

Stefania Scaglione

showing 2 related works from this author

Pathogenetic Mechanisms of Hypertension-Brain-Induced Complications: Focus on Molecular Mediators.

2021

There is growing evidence that hypertension is the most important vascular risk factor for the development and progression of cardiovascular and cerebrovascular diseases. The brain is an early target of hypertension-induced organ damage and may manifest as stroke, subclinical cerebrovascular abnormalities and cognitive decline. The pathophysiological mechanisms of these harmful effects remain to be completely clarified. Hypertension is well known to alter the structure and function of cerebral blood vessels not only through its haemodynamics effects but also for its relationships with endothelial dysfunction, oxidative stress and inflammation. In the last several years, new possible mechani…

Settore MED/09 - Medicina InternaOrganic ChemistryToll-Like ReceptorsHemodynamicsBrainGeneral MedicineCatalysisCerebral complications Endothelial dysfunction Hypertension Innate immune system Neuroinflammation Oxidative stress Toll-like receptorsImmunity InnateComputer Science ApplicationsInorganic ChemistryOxidative StressHypertensionDisease ProgressionAnimalsHumansPhysical and Theoretical ChemistryMolecular BiologySpectroscopyInternational journal of molecular sciences
researchProduct

Efficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trial

2021

Abstract Background Recent cardiovascular outcome trials have shown significant reductions in major cardiovascular (CV) events with glucagon-like peptide (GLP)-1 receptor agonists. Additionally, adjunctive surrogates for cardiovascular risk validated by some studies include arterial stiffness and endothelial function indexes. To date, no randomized trial has addressed the possible effects of antidiabetic interventional drugs such as GLP1 agonists on endothelial and arterial stiffness indexes as surrogate markers of vascular damage. Aims We aimed to evaluate metabolic efficacy and surrogate vascular efficacy endpoints of once-weekly dulaglutide (1.5 mg) plus traditional antidiabetic treatmen…

Blood GlucoseMalelcsh:Diseases of the circulatory (Cardiovascular) systemSettore MED/09 - Medicina InternaTime FactorsEndocrinology Diabetes and MetabolismGlucagon-Like PeptidesBlood PressureType 2 diabetesGastroenterologylaw.inventionRandomized controlled triallawPulse wave velocityOriginal InvestigationDiabetesMiddle AgedLipidsVasodilationTreatment OutcomeItalyDrug Therapy CombinationFemaleCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyRecombinant Fusion ProteinsIncretinsGlucagon-Like Peptide-1 ReceptorVascular StiffnessDiabetes mellitusInternal medicinemedicineHumansHypoglycemic AgentsDulaglutideAngiologyAgedVascular healthGlycated Hemoglobinbusiness.industrymedicine.diseasedulaglutide diabetes arterial stiffnessImmunoglobulin Fc FragmentsBlood pressureDiabetes Mellitus Type 2lcsh:RC666-701Arterial stiffnessDulaglutidebusinessBiomarkersCardiovascular Diabetology
researchProduct